US
US Hormone Testing at Home Market Industry Trends and Forecast to 2034: Segmented by (Hormone, Sample, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
US · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
US (this report) at $379.4 Mn.
Canada at 9.9% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$366.5 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $352.0 Mn | — | — |
| 2025 (base) | $379.4 Mn | +$27.5 Mn | — |
| 2026 (forecast) | $409.0 Mn | +$29.6 Mn | +7.8% |
| 2027 (forecast) | $440.9 Mn | +$31.9 Mn | +16.2% |
| 2028 (forecast) | $475.3 Mn | +$34.4 Mn | +25.3% |
| 2029 (forecast) | $512.4 Mn | +$37.1 Mn | +35% |
| 2030 (forecast) | $552.4 Mn | +$40.0 Mn | +45.6% |
| 2031 (forecast) | $595.4 Mn | +$43.1 Mn | +56.9% |
| 2032 (forecast) | $641.9 Mn | +$46.4 Mn | +69.2% |
| 2033 (forecast) | $691.9 Mn | +$50.1 Mn | +82.4% |
| 2034 (forecast) | $745.9 Mn | +$54.0 Mn | +96.6% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US (this report)
$379.4 Mn
Canada
$65.0 Mn
China
$61.6 Mn
Japan
$45.4 Mn
Germany
$32.0 Mn
UK
$22.9 Mn
France
$21.5 Mn
Brazil
$21.9 Mn
Italy
$17.2 Mn
Ecuador
$17.2 Mn
Spain
$16.3 Mn
India
$16.0 Mn
Mexico
$14.4 Mn
Saudi Arabia
$13.7 Mn
Australia
$11.7 Mn
New Zealand
$8.2 Mn
Russia
$7.5 Mn
South Africa
$5.7 Mn
UAE
$4.8 Mn
Egypt
$2.4 Mn
Philippines
$2.1 Mn
Hong Kong
$1.4 Mn
Malaysia
$1.2 Mn
Singapore
$1.1 Mn
Thailand
$1.1 Mn
Kenya
$0.6 Mn
At-home hormone tests measure hormones such as estrogen, thyroid, cortisol and testosterone from finger-prick blood or saliva.
Key segments of the hormone Testing at Home market include hormone (Female Sex Hormones, Thyroid and Cortisol) and sample (Blood, Saliva and Urine).
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the hormone Testing at Home market. New products designed around women's biology and digital care are improving access.
Femtech, personalised care and new treatments for under-served conditions open strong growth for the hormone Testing at Home market, especially as employers and payers add women's health benefits.
Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the hormone Testing at Home market.
The hormone Testing at Home market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how hormone Testing at Home products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in US.
What doctors and scientists are doing in Hormone Testing at Home right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.
From our blog
US · 2 shared keywords
US · 1 shared keyword
US
US
US
US
Digital Health · US
Healthcare Services · US
Healthcare Services · US
Pharmaceuticals · US
Pharmaceuticals · US
Healthcare Services · US